Search Results
Baxter Supports New Study Showing Blood Purification with Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients
Baxter International Inc. (NYSE:BAX), a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood purification (EBP) using the company’s Oxiris filter set.
The FRESH Clinical Trial: An Investigator’s Perspective
Reactions from Professor Lui Forni, BSc, Ph.D., MB.BS, MRCPI, AFICM
Baxter to Present at 29th Annual Credit Suisse Virtual Healthcare Conferencce
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on Monday, November 9, 2020. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 11:45 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 9, 2021.
Supporting Sepsis Patients
Medical director reflects on his experience treating patients with sepsis on the heels of Sepsis Awareness Month
Shahid’s Smile: How our Partnership is Making a Difference
Meet the first patient to receive surgery at Operation Smile’s Durgapur Cleft Center, which was opened in 2019 with support from the Baxter International Foundation
Encouraging Diverse Perspectives
Principal engineer shares thoughts on being an inclusive and authentic team leader
Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition
A global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections.
Baxter Announces Support for Finalization of Core Component of the Advancing American Kidney Health Initiative
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today issued this statement: